VectorBuilder News and Resources

Genetic Immunity, clinical-stage biotechnology company focusing on discovering and developing plasmid-based DNA (pDNA) therapeutic vaccines for cancer and infectious diseases, is taking its HIV vaccine into Phase 3 clinical trials following promising results from earlier studies. The company has partnered

VectorBuilder, providing end-to-end gene delivery services, has joined forces with Sartorius, an international partner in life science research and the biopharmaceutical industry, to expand their longstanding partnership. The newly announced strategic agreement is set to accelerate innovations in gene vector